244 related articles for article (PubMed ID: 21558077)
1. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.
Johnson DR; Kimmel DW; Burch PA; Cascino TL; Giannini C; Wu W; Buckner JC
Neuro Oncol; 2011 May; 13(5):530-5. PubMed ID: 21558077
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Norden AD; Ligon KL; Hammond SN; Muzikansky A; Reardon DA; Kaley TJ; Batchelor TT; Plotkin SR; Raizer JJ; Wong ET; Drappatz J; Lesser GJ; Haidar S; Beroukhim R; Lee EQ; Doherty L; Lafrankie D; Gaffey SC; Gerard M; Smith KH; McCluskey C; Phuphanich S; Wen PY
Neurology; 2015 Jan; 84(3):280-6. PubMed ID: 25527270
[TBL] [Abstract][Full Text] [Related]
3. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
Simó M; Argyriou AA; Macià M; Plans G; Majós C; Vidal N; Gil M; Bruna J
Cancer Chemother Pharmacol; 2014 May; 73(5):919-23. PubMed ID: 24619496
[TBL] [Abstract][Full Text] [Related]
4. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
Graillon T; Sanson M; Campello C; Idbaih A; Peyre M; Peyrière H; Basset N; Autran D; Roche C; Kalamarides M; Roche PH; Fuentes S; Tabouret E; Barrie M; Cohen A; Honoré S; Boucekine M; Baumstarck K; Figarella-Branger D; Barlier A; Dufour H; Chinot OL
Clin Cancer Res; 2020 Feb; 26(3):552-557. PubMed ID: 31969329
[TBL] [Abstract][Full Text] [Related]
5. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.
Chamberlain MC; Glantz MJ; Fadul CE
Neurology; 2007 Sep; 69(10):969-73. PubMed ID: 17785665
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease.
Rammo R; Rock A; Transou A; Raghunathan A; Rock J
J Neurosurg; 2016 Feb; 124(2):496-500. PubMed ID: 26274993
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Reardon DA; Norden AD; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Sampson JH; Gururangan S; Peters KB; McLendon RE; Norfleet JA; Lipp ES; Drappatz J; Wen PY; Friedman HS
J Neurooncol; 2012 Jan; 106(2):409-15. PubMed ID: 21938530
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Kaley TJ; Wen P; Schiff D; Ligon K; Haidar S; Karimi S; Lassman AB; Nolan CP; DeAngelis LM; Gavrilovic I; Norden A; Drappatz J; Lee EQ; Purow B; Plotkin SR; Batchelor T; Abrey LE; Omuro A
Neuro Oncol; 2015 Jan; 17(1):116-21. PubMed ID: 25100872
[TBL] [Abstract][Full Text] [Related]
9. Management of recurrent meningeal hemangiopericytoma.
Galanis E; Buckner JC; Scheithauer BW; Kimmel DW; Schomberg PJ; Piepgras DG
Cancer; 1998 May; 82(10):1915-20. PubMed ID: 9587125
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Chamberlain MC
Neurology; 2015 Sep; 85(12):1090. PubMed ID: 26391415
[No Abstract] [Full Text] [Related]
11. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
Mason WP; Gentili F; Macdonald DR; Hariharan S; Cruz CR; Abrey LE
J Neurosurg; 2002 Aug; 97(2):341-6. PubMed ID: 12186462
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: prognosis and identification by ¹¹¹Indium-octreotide imaging.
Alexandru D; Glantz MJ; Kim L; Chamberlain MC; Bota DA
Cancer; 2011 Oct; 117(19):4506-11. PubMed ID: 21446045
[TBL] [Abstract][Full Text] [Related]
13. Visual improvement during octreotide therapy in a case of episellar meningioma.
Jaffrain-Rea ML; Minniti G; Santoro A; Bastianello S; Tamburrano G; Gulino A; Cantore G
Clin Neurol Neurosurg; 1998 Mar; 100(1):40-3. PubMed ID: 9637203
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
Seystahl K; Stoecklein V; Schüller U; Rushing E; Nicolas G; Schäfer N; Ilhan H; Pangalu A; Weller M; Tonn JC; Sommerauer M; Albert NL
Neuro Oncol; 2016 Nov; 18(11):1538-1547. PubMed ID: 27106404
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M
Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583
[TBL] [Abstract][Full Text] [Related]
16. Comment: Medical therapy for recurrent or progressive meningiomas remains elusive.
Iwamoto FM
Neurology; 2015 Jan; 84(3):285. PubMed ID: 25527267
[No Abstract] [Full Text] [Related]
17. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Wen PY; Yung WK; Lamborn KR; Norden AD; Cloughesy TF; Abrey LE; Fine HA; Chang SM; Robins HI; Fink K; Deangelis LM; Mehta M; Di Tomaso E; Drappatz J; Kesari S; Ligon KL; Aldape K; Jain RK; Stiles CD; Egorin MJ; Prados MD
Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
[TBL] [Abstract][Full Text] [Related]
18. Atypical and anaplastic meningiomas treated with bevacizumab.
Nayak L; Iwamoto FM; Rudnick JD; Norden AD; Lee EQ; Drappatz J; Omuro A; Kaley TJ
J Neurooncol; 2012 Aug; 109(1):187-93. PubMed ID: 22544653
[TBL] [Abstract][Full Text] [Related]
19. [X-ray computed tomographic aspects of malignant meningioma and meningeal hemangiopericytoma].
Dufresne MC; Bédard F
Can Assoc Radiol J; 1996 Aug; 47(4):279-87. PubMed ID: 8696997
[TBL] [Abstract][Full Text] [Related]
20. Resected atypical meningioma relapsed to anaplastic meningioma during luteinizing hormone-releasing hormone agonist therapy.
Nicosia L; Bucpapaj R; Barresi V; Damante R; Napoli G; Ghimenton C; Giaj-Levra N; Cancedda M; Flaminio S; Figlia V; Alongi F
Neurochirurgie; 2021 Apr; 67(2):193-197. PubMed ID: 33190809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
